Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Novo Nordisk entered an exclusive license with Hengrui Pharma for HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP agonist, including $300M upfront and up to $2.6B in milestones. Rights cover all markets except mainland China, Hong Kong, Macao and Taiwan.Material DetailsContext by AI AnalystThi…
Novo Nordisk gets exclusive rights outside mainland China, Hong Kong, Macau and Taiwan. Hengrui will receive $300 million upfront plus milestones and royalties; closing is expected in Q4 2026, subject to U.S. antitrust clearance and other conditions.